Approval · Notice of Compliance 31372 · 2023
MINT-AMOXI/CLAV: Notice of Compliance 31372
Issued August 4, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31372
- Date
- August 4, 2023
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Update to Labels. Response to Advisement Letter
- Canadian reference product
- CLAVULIN (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-AMOXI/CLAV | Not yet assigned | — |
Medicinal ingredients
- CLAVULANATE POTASSIUM 125 MG per TAB
- AMOXICILLIN TRIHYDRATE 250 MG per TAB
- AMOXICILLIN TRIHYDRATE 500 MG per TAB
- AMOXICILLIN TRIHYDRATE 875 MG per TAB